A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

Transplantation

Volumn 87, Issue 2, 2009, Pages 296-302

  Tiong, Ho Yee ^a   Flechner, Stuart M ^a   Zhou, Lingme ^b   Wee, Alvin ^a   Mastroianni, Barbara ^a   Savas, Kathy ^a   Goldfarb, David ^a   Derweesh, Ithaar ^a   Modlin, Charles ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Lymphoceles; Postoperative complications; Sirolimus; Wound healing

Indexed keywords

BASILIXIMAB; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; STEROID;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEALTH PROGRAM; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOADING DRUG DOSE; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT SELECTION; PRIORITY JOURNAL; SUCTION DRAINAGE; WOUND HEALING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEALTH CARE QUALITY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; SUCTION;

ADULT; BODY MASS INDEX; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ODDS RATIO; PROGRAM EVALUATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; STEROIDS; SUCTION; WOUND HEALING; YOUNG ADULT;

EID: 59649093458     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318192dd56     Document Type: Article

References (36)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Kidney Survival Table 5.9A. 2007 Annual Report of the US OPTN and the SRTS: Transplant Data 1997-2006. HRSA, Healthcare Systems Bureau, Rockville, MD, 2007.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
5. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
6. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
7. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
8. Webster AC, Lee VWS, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
9. Oberbauer R, Segoloni G,Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
10. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76: 1729.
11. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study. Transplantation 2003; 76: 426.
12. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128.
13. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: Aprospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
14. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804.
15. Goel M, Flechner SM, Zhou L, et al. The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation. J Urol 2004; 171: 1788.
16. Larson TS, DeanPG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
18. Derweesh, IH, Ismail HR, Araki M, et al. Intraoperative placing of drains decreases the incidence oflymphocele and deep vein thrombosis after renal transplantation. Br J Urol 2008; 101: 1415.
19. Flechner SM, Duclos A. Renal transplantation. In: Montague DK, Angermeier K, Gill IS, et al., eds. Reconstructive urologic surgery: Adult and pediatric. Oxford, United Kingdom, Taylor and Francis Books Ltd. Chapter 15, pp. 133.
20. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005; 79: 926.
21. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endo-thelial cells and fibroblasts. Transplant Proc 1991; 23: 2833.
22. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002; 16: 771.
23. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655.
24. HuberS, Bruns CJ, Schmid G,et al. Inhibition ofthe mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71: 771.
25. Macdonald AS; Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for prevention of acute rejection in recipients of mismatched renal allografts. Transplantation 2001; 71: 271.
26. Kahan BD. Efficacyofsirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
27. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662.
28. Knechtle SJ, Pirsch JD, Fechner J, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
29. HumarA, RamcharanT, DennyR, et al. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 2001; 72: 1920.
30. Kihara A, Kasamaki S, Kamano T, et al. Abdominal wound dehiscence in patients receiving long-term steroid treatment. J Int Med Res 2006; 34: 223.
31. Leibovich SJ, Ross R. The role of the macrophage in wound repair. A study with hydrocortisone and anti-macrophage serum. Am J Pathol 1975; 78: 71.
32. Ehrlich HP, Tarver H, Hunt TK. Effects of vitamin A and glucocorti-coids upon inflammation and collagen synthesis. Ann Surg 1973; 177: 222.
33. Rogers CC, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc 2005; 37: 795.
34. Gaber MW, Aziz AM, Shang X, et al. Changes in abdominal wounds following treatment with sirolimus and steroids in a rat model. Transplant Proc 2006; 38: 3331.
35. Schaffer M, Schier R, Napirei M, et al. Sirolimus impairs wound healing. Langenbecks Arch Surg 2007; 392: 297.
36. Diekmann F, Campistol JM, Saval N, et al. Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation. Transplantation 2007; 84: 429.